Instil Bio and ImmuneOnco Announce License and Collaboration Agreement for Development of IMM2510 and IMM27M August 7, 2024
SOTIO Enters into Multi-Target Antibody Agreement with Biocytogen to Expand ADC Pipeline July 23, 2024
Full-Life Technologies, SK Biopharmaceuticals Enter Licensing Agreement for Novel Therapeutic Targeting Multiple Solid Tumors July 23, 2024
Ipsen and Foreseen Biotechnology announce exclusive global licensing agreement for novel ADC July 17, 2024
IND Submission to US FDA for Ph 1/2 study of Silmitasertib (CX-4945) in children and young adults with R/R solid tumors July 17, 2024
Development of Early-Stage Bispecific T-Cell Engager AMG 794 for Solid Tumors discontinued July 17, 2024
Safety Approval Announced for the First Dose Cohort in Ph 1a/b Clinical Trial of PMC-309 in Patients with Advanced or Metastatic Solid Tumors July 17, 2024
US FDA grants IND Clearance to Conduct Ph 1/2 Study of JCXH-211 IV as Monotherapy and with Checkpoint Inhibitor in Patients with Advanced Solid Tumors July 17, 2024
Boehringer Ingelheim and OSE Immunotherapeutics advance clinical development of first-in-class SIRP cancer immunology treatment BI 770371 July 9, 2024
Initial Safety and Efficacy Data from Ph 1 Trial of WTX-330 in Patients with Advanced or Metastatic Solid Tumors or NHL announced July 1, 2024
FDA Fast Track Designation for CT-0525 for the Treatment of HER2-overexpressing Solid Tumors July 1, 2024
FDA places partial clinical hold on Ph 1 ZN-c3-001 in solid tumors, Ph 2 ZN-c3-005 (DENALI) study in platinum-resistant ovarian cancer (PROC) and Ph 2 ZN-c3-004 (TETON) study in uterine serous carcinoma (USC) of azenosertib June 25, 2024
Day One Expands Pipeline with Potential First-in-Class Clinical-Stage ADC Targeting PTK7 in Solid Tumors for Adult and Pediatric Cancers June 25, 2024
EMA validates extension application for SC formulation for Opdivo including liquid formulation and new strength across previously approved indications June 25, 2024
Lead Selection for MDG2021 Announced, Expanding TCR-T KRAS Library Targeting Solid Tumors June 25, 2024
China’s NMPA approves IND for GFH375 for Ph 1/2 Clinical Trial Treating Advanced Solid Tumor Patients with KRAS G12D Mutation June 25, 2024
US FDA Approves Augtyro™ (repotrectinib) for the Treatment of Patients with NTRK-Positive Locally Advanced or Metastatic Solid Tumors June 18, 2024
Calidi Biotherapeutics Collaborates with SIGA Technologies to Advance RTNova Virotherapy for Lung Cancer and Metastatic Solid Tumors June 18, 2024
